Stock Screener App

Frei - Play StoreApp Store

Installieren Installieren

PRME

$4.445.93%-0.28

Vorbörslich: 4.37-0.07 -1.58%

Prime Medicine Inc (PRME)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$4.72

Offen:

$4.86

24-Stunden-Volumen:

4,124,767

Relatives Volumen:

0.66

Marktkapitalisierung:

$805.31M

Einnahmen:

$4.03M

Nettoeinkommen (Verlust:

-$198.37M

KGV:

-

EPS:

-$1.26

Netto-Cashflow:

-$158.74M

1W Leistung:

+2.07%

1M Leistung:

+48.99%

6M Leistung:

+30.21%

1Y Leistung:

-2.63%

1-Tages-Spanne:

$0.00$0.00

1-Wochen-Bereich:

$4.11$5.91

52-Wochen-Spanne:

$2.67$5.91

Prime Medicine Inc Aktie (PRME) Unternehmensprofil

Firmenname

Prime Medicine Inc

Sektor

Branche

Telefon

617-465-0013

Adresse

60 FIRST ST., CAMBRIDGE, USA

Mitarbeiter

146

X

-

Nächster Verdiensttermin

2026-11-06

Neueste SEC-Einreichungen

PRME-Diskussionen auf X

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Prime Medicine Inc Aktie (PRME) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-08-25	Resumed	Chardan Capital Markets	Buy
2026-08-19	Eingeleitet	BMO Capital Markets	Outperform
2026-06-29	Hochstufung	H.C. Wainwright	Neutral → Buy
2026-03-12	Eingeleitet	Oppenheimer	Outperform
2025-05-27	Herabstufung	Citigroup	Buy → Neutral
2025-05-20	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-05-20	Herabstufung	JP Morgan	Overweight → Neutral
2024-12-10	Eingeleitet	JMP Securities	Mkt Outperform
2024-05-20	Eingeleitet	H.C. Wainwright	Buy
2024-05-16	Hochstufung	Citigroup	Neutral → Buy
2024-04-22	Eingeleitet	Chardan Capital Markets	Buy
2024-04-08	Eingeleitet	TD Cowen	Buy
2024-04-03	Eingeleitet	Wedbush	Outperform
2024-01-16	Herabstufung	Stifel	Buy → Hold
2023-12-08	Eingeleitet	Citigroup	Neutral
2023-10-09	Eingeleitet	BMO Capital Markets	Outperform
2023-07-31	Eingeleitet	Guggenheim	Buy
2023-04-18	Eingeleitet	Stifel	Buy
2022-11-14	Eingeleitet	Goldman	Neutral
2022-11-14	Eingeleitet	JP Morgan	Overweight
2022-11-14	Eingeleitet	Jefferies	Buy
2022-11-14	Eingeleitet	Morgan Stanley	Equal-Weight

Finanzdaten der Prime Medicine Inc-Aktie (PRME)

Zeitraum	Trend	FY 2025	FY 2024	FY 2023	FY 2022
Enddatum des Zeitraums		2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue USD (M)		4.63	2.98	0.00	0.00
Research and development USD (M)		160.64	155.29	147.91	86.73
Operating expenses USD (M)		212.98	205.45	204.79	116.54
Operating income USD (M)		-208.35	-202.47	-204.79	-116.54
Income before tax USD (M)		-	-	-198.41	-122.77
Income tax expense USD (M)		0.00	0.00	-0.28	-0.95
Net income USD (M)		-201.14	-195.88	-198.13	-121.82
Basic EPS USD/shares		-1.35	-1.65	-2.18	-4.19
Diluted EPS USD/shares		-1.35	-1.65	-2.18	-4.19
Basic weighted shares shares (M)		148.76	118.60	90.97	33.89
Diluted weighted shares shares (M)		148.76	118.60	90.97	33.89

Prime Medicine Inc Aktie (PRME) Neueste Nachrichten

Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains? - Zacks Investment Research

Prime Medicine, Inc. (PRME) - What Are Brokerages Thinking About This Stock? - MarketBeat

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - TradingView

Prime Medicine (NASDAQ:PRME) Stock Falls 7.6% - Here's Why - MarketBeat

Prime Medicine (PRME) Stock Draws Traders On FDA Trial Wins - Timothy Sykes

PRME Stock Climbs As FDA Greenlights Gene-Editing Trials - StocksToTrade

Prime Medicine, Inc. (PRME) stock price, news, quote and history - Yahoo Finance Australia

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease - GlobeNewswire Inc.

Prime Medicine (NASDAQ:PRME) Stock Price Up 6.1% - Still a Buy? - MarketBeat

PRME Stock Dips As Prime Medicine Faces Steep Losses - StocksToTrade

Prime Medicine Stock Slips As Traders Digest Weak Margins - StocksToTrade

Prime Medicine: A Buy Due To BLA Filing H1 '27 And In Vivo Therapy Development (PRME) - Seeking Alpha

Prime Medicine stock surges on FDA IND clearance - Yahoo Finance

FDA clears testing of a genetic treatment aimed at a variant carried by about 100,000 people in the U.S. - Stock Titan

Prime Medicine (NasdaqGM:PRME) Stock Forecast & Analyst Predictions - Simply Wall Street

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency - Yahoo Finance

Prime Medicine, Inc. (NASDAQ:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Prime Medicine (Nasdaq:PRME) - Stock Analysis - Simply Wall Street

Prime Medicine (NASDAQ:PRME): What's Behind Its Sudden Share Price Jump? - kalkinemedia.com

Prime Medicine (NASDAQ:PRME) Shares Up 11.8% - Should You Buy? - MarketBeat

Prime Medicine (NASDAQ:PRME) Rating Increased to Hold at Wall Street Zen - MarketBeat

Prime Medicine (NASDAQ:PRME) Stock Price Down 4.3% - Here's What Happened - MarketBeat

A gene-editing company sets three September conference appearances - Stock Titan

Prime Medicine to Participate in Upcoming Investor Conferences - Yahoo Finance

BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME - MarketBeat

Prime Medicine, Inc. (PRME) Stock Price & News - Syfe

Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Prime Medicine (NASDAQ:PRME) Upgraded to Strong-Buy at Chardan Capital - marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Prime Medicine, Inc. $PRME - MarketBeat

Prime Medicine (NASDAQ:PRME) Stock Price Down 4.7% - What's Next? - MarketBeat

Prime Medicine (NASDAQ:PRME) Shares Up 6.3% - Here's What Happened - MarketBeat

Prime Medicine (NASDAQ:PRME) Trading Down 6.9% - Should You Sell? - MarketBeat

Prime Medicine (NASDAQ:PRME) Rating Increased to Strong-Buy at BMO Capital Markets - MarketBeat

Prime Medicine Company Profile & Introduction - Moomoo

Prime Medicine (NASDAQ:PRME) Shares Gap Up - Still a Buy? - MarketBeat

PRIME MEDICINE, INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $9 - Bitget

PRME Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus

Prime (PRME) Results Breakdown: The Available Earnings Metric Delivers a Beat for the Current Session; Investor Response: Shares Fall 3.79% on the Day - Consensus Beat Rate - vinanet.vn

BMO initiates Prime Medicine stock with outperform rating By Investing.com - Investing.com Canada

Alphabet Inc. Takes Position in Prime Medicine, Inc. $PRME - MarketBeat

Prime Medicine Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Prime Medicine: Soon In The Clinic (NASDAQ:PRME) - Seeking Alpha

Prime Medicine, Inc. Stock 12‑Month Price Target Cut to $6.92, Implies 124% Upside - TradingView

PRME Q2 2026 Earnings: Narrower-than-Expected Loss Marks Progress as Stock Slips - Profit Announcement - vinanet.vn

Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright - MarketBeat

Prime Medicine: An Initial Prognosis (NASDAQ:PRME) - Seeking Alpha

Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail

Prime Medicine (NASDAQ:PRME) Trading Up 7.3% - Still a Buy? - MarketBeat

Ähnlich wie PRME

AKTS$14.598.41%

BBTX$16.000.00%